Divi's Labs is a sure-shot pill to profit

The scrip is at Rs 774 with a price and volume break-out today.
It is resting on 20D EMA and with NIFTY's assistance in coming weeks, may gallop to close the huge fall experienced earlier from Rs 1100 levels mainly due to US FDA inspection and recommendations.
The company has completed the recommendations satisfactorily and is waiting for market fancy .
Technically and fundamentally, it is underpriced. Book Value is a healthy Rs 195, PE=18, a debt-free balance sheet , growing turnover and profits, it should return to its previous glory pretty soon.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.